A team of leading infectious disease scientists from academia and industry have been awarded £17.9 million to identify new ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

SA has accepted an offer of just over R520-million from the Global Fund to Fight Aids, TB and Malaria to buy the twice-a-year anti-HIV jab, lenacapavir. Research shows the shot could help end Aids in ...

The world is facing more and more conflicts. The Russia-Ukraine war is the biggest in Europe since World War II. In the ...

South Africa expressed confidence that it can get finance ministers and central bank governors from the Group of 20 nations ...

Entrepreneur Godiragetse Mogajane saw an opportunity to offer delivery and logistics services in South Africa’s townships.

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

We have launched a new five-year partnership with GlaxoSmithKline (GSK) to enhance the capabilities of African scientists in modern analytical skills.

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious disease R&D.

A proposed regulatory change would allow Elon Musk’s satellite company and others like it to get a license without having to sell shares to Black South Africans.

President Trump confronted South African President Cyril Ramaphosa, who pushed back on claims about White genocide in South Africa.

Tech billionaire Elon Musk was born in South Africa but emigrated at age 17 and eventually became a naturalized U.S. citizen.